Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Formula rebounds, Amerifit grows in Martek Q2

This article was originally published in The Tan Sheet

Executive Summary

The infant formula market's rebound from 2009 lows helps boost Martek Biosciences' total product sales 35.1 percent to $119.1 million in the February-April period. Second-quarter sales of Martek's formula ingredients reached $86.3 million, up 11.5 percent, helped by gains in Asia, executives said June 3. Amerifit Brands, which Columbia, Md.-based Martek acquired in January, generated $18 million in revenue and $1.9 million in operating income. Martek plans to launch finished supplement products through Amerifit in 2011 (1"The Tan Sheet" Jan. 25, 2010). Additionally, the company continues seeking new applications for its algal life'sDHA. Martek announced June 2 the omega-3 ingredient will fortify sauces and dressings at sandwich chain Quiznos

You may also be interested in...

Martek Pursues Direct Consumer Access With Pending Acquisition Of Amerifit

Martek Biosciences' proposed acquisition of Amerifit Brands for $200 million would mark the omega-3 DHA ingredient supplier's first major foray into consumer marketing and would substantially expand the firm's portfolio

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts